FAIC Act
- Sponsor
- Rep. Dunn, Neal P. [R-FL-2]
- Committees
- Ways and Means Committee (primary)
- Last action
- Mar 20, 2026
Bottom line
The bill aims to improve Medicare beneficiary access to newer, expensive cancer treatments in outpatient settings by ensuring hospitals receive separate, adequate reimbursement, with the caveat that overall Medicare spending remains neutral through internal payment adjustments.
What it actually does
This bill amends the Social Security Act to require Medicare's hospital outpatient prospective payment system (OPPS) to make separate payments for certain high-cost cancer drugs and biologics, rather than packaging their costs into bundled payments. It defines eligible treatments based on FDA approval date, cost threshold, and current payment status, while mandating budget neutrality for the overall OPPS expenditures.
Proponents argue
Supporters argue that this legislation is crucial for ensuring Medicare beneficiaries have consistent access to the latest, most effective cancer therapies. By requiring separate and equitable payment for high-cost innovative treatments, it removes financial disincentives for hospitals to offer these drugs, thereby preserving access and supporting advancements in cancer care.
Opponents contend
Critics might contend that while the bill mandates budget neutrality, the mechanism for achieving this will necessitate reductions in payments for other essential outpatient services. This could lead to a redistribution of resources within the OPPS, potentially impacting other patient populations or creating financial strain for providers of non-cancer-related services.
The bill is very short and clearly written, allowing for quick and easy comprehension of its core policy changes.
Section 2, amending Section 1833(t)(16) of the Social Security Act
Separate Payment for Certain Cancer Treatments
This provision mandates that Medicare's hospital outpatient prospective payment system (OPPS) must make separate payments for specific cancer drugs and biologics, rather than bundling their costs into a larger payment for a group of services. To qualify, a treatment must be FDA-approved for cancer on or after January 1, 2008, not currently receive transitional pass-through payments, and have an estimated mean per day product cost exceeding a specified threshold ($350 in 2026, adjusted annually). The payment amount will be based on the average sales price (ASP) or wholesale acquisition cost (WAC).
Supporters argue
Supporters argue this provision is crucial for ensuring that Medicare beneficiaries have access to the latest cancer therapies. By providing separate, adequate payment for high-cost drugs, it removes financial barriers for hospitals to administer these treatments, fostering innovation and improving patient outcomes.
Critics contend
Critics might contend that while the intent is good, the budget neutrality requirement means that increased payments for these specific cancer treatments will necessitate cuts elsewhere in the OPPS, potentially negatively impacting other essential outpatient services or creating winners and losers among different types of providers or patient populations.
Tradeoffs
The bill balances the goal of ensuring access to innovative cancer treatments with the need for budget neutrality within the Medicare OPPS. The tension lies in how the required budget neutrality adjustments will be implemented and which other services might see reduced payments as a result.
This clause requires the Secretary of Health and Human Services to make necessary adjustments to ensure that the total amount of expenditures under the hospital outpatient prospective payment system (OPPS) for a year, with the application of this new separate payment policy, is equal to the amount of expenditures that would have been made without it.
Section 2, clause (iv) "Budget neutrality."
Why it matters:This is standard legislative practice for Medicare payment changes to prevent unintended cost increases, but its implications for other services are significant and left to administrative discretion.
Case for: Proponents argue this clause ensures fiscal responsibility by preventing the bill from increasing overall Medicare spending, making the policy change more palatable and sustainable.
Case against: Critics contend that the lack of specificity regarding how budget neutrality will be achieved grants significant discretion to the Secretary, potentially leading to arbitrary cuts in other valuable services to offset the increased payments for cancer treatments.
Estimated impact: This provision dictates that the net impact on overall Medicare spending will be zero, but it implies a redistribution of funds within the OPPS, with increased payments for cancer treatments offset by reductions elsewhere.